{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:53:28Z","timestamp":1790121208263,"version":"4.0.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the clinical features of active tuberculosis (TB) infection due to immune checkpoint inhibitors (ICIs) treatment in patients with advanced cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We report the diagnosis and treatment of a case of pulmonary malignancy (squamous cell carcinoma, cT4N3M0 IIIC), secondary to active TB infection following ICIs therapy. Moreover, we summarize and analyze other related cases collected from the China National Knowledge Infrastructure (CNKI), Wanfang Database, PubMed, the Web of Science, and EMBASE (up to October 2021).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 23 patients, including 20 males and 3 females who were aged 49-87 years with a median age of 65 years, were included in the study. Twenty-two patients were diagnosed by Mycobacterium tuberculosis culture or DNA polymerase chain reaction (PCR), while the remaining patient was diagnosed by tuberculin purified protein derivative and pleural biopsy. One case had an interferon-gamma release assay (IGRA) to rule out latent TB infection prior to the application of ICI. Fifteen patients received an anti-tuberculosis regimen. Among the 20 patients with a description of clinical regression, 13 improved and 7 died. Seven of the patients who improved were treated with ICI again and four of them did not experience a recurrence or worsening of TB. The case diagnosed in our hospital also improved after receiving anti-TB treatment after stopping ICI therapy, and continued chemotherapy on the basis of anti-TB treatment, and his condition is relatively stable at present.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Due to the lack of specificity of TB infection following ICIs therapy, patients should be followed for fever and respiratory symptoms for 6.3 months after drug administration. It is recommended that IGRA should be performed before ICIs therapy and the development of TB during immunotherapy in patients who are positive in IGRA should be closely monitored. The symptoms of TB in most patients can be improved with ICIs withdrawal and anti-TB treatment, but there is still a need to be alert to the potentially fatal risk of TB.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1162190","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T04:52:08Z","timestamp":1684990328000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review"],"prefix":"10.3389","volume":"14","author":[{"given":"Chen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PloS Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"ciw838","DOI":"10.1093\/cid\/ciw838","article-title":"Risk of active tuberculosis in patients with cancer: a systematic review and meta-analysis","volume":"64","author":"Cheng","year":"2016","journal-title":"CLINID"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1700157","DOI":"10.1183\/13993003.00157-2017","article-title":"Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis","volume":"50","author":"Dobler","year":"2017","journal-title":"Eur Respir J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2016.11046","article-title":"Screening for latent tuberculosis infection in adults: US preventive services task force recommendation statement","volume":"316","author":"Preventive Services Task Force","year":"2016","journal-title":"JAMA"},{"key":"B5","article-title":"Definition of immune checkpoint inhibi-tor-nci dictionary of cancer terms[EB\/OL]","year":"2022"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003304","article-title":"CD4 T cells promote rather than control tuberculosis in the absence of PD-1\u2013mediated inhibition","volume":"186","author":"Barber","year":"2011","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/17843286.2019.1629078","article-title":"Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases","volume":"75","author":"Inthasot","year":"2020","journal-title":"Acta Clin Belg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1250LE","article-title":"Implications of tuberculosis reactivation after immune checkpoint inhibition","volume":"198","author":"Elkington","year":"2018","journal-title":"Am J Respir Crit Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s40425-019-0717-7","article-title":"Reactivation of tuberculosis in cancer patients following administration ofimmune checkpoint inhibitors: Current evidence and clinical practicerecommendations [J]","volume":"7","author":"Anastasopoulou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.03.012","article-title":"Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti\u2013PD-1 treatment in a patient with advanced pulmonary adenocarcinoma","volume":"12","author":"Chu","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1301562","article-title":"Significant neutrophilic emperipolesis in squamous cell carcinoma","volume":"2018","author":"Tetikkurt","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S178246","article-title":"Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report","volume":"11","author":"He","year":"2018","journal-title":"OTT"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.07.006","article-title":"Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Fujita","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02726-1","article-title":"Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. case report and literature review","volume":"70","author":"Suliman","year":"2021","journal-title":"Cancer Immunol Immun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1125017","article-title":"Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed hodgkin\u2019s lymphoma","volume":"55","author":"Lee","year":"2016","journal-title":"Acta Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcy243","article-title":"Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment","volume":"112","author":"Tsai","year":"2019","journal-title":"QJM: Int J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B19","doi-asserted-by":"publisher","first-page":"105853","DOI":"10.1016\/j.rmed.2019.105853","article-title":"Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors","volume":"161","author":"Im","year":"2020","journal-title":"Respir Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S1034","DOI":"10.1016\/j.jtho.2018.08.1995","article-title":"P3.CR-16 A Case of Toxic Hepatic Event Occurring in Combination Treatment with Nivolumab and Anti-Tuberculosis in Advanced Lung Cancer","volume":"13","author":"Kim","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2018.06.016","article-title":"Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-mycobacterium tuberculosis agents","volume":"25","author":"Takata","year":"2019","journal-title":"J Infect Chemother"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00659","article-title":"Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review","volume":"9","author":"van Eeden","year":"2019","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800762","article-title":"Prednisone for the prevention of paradoxical tuberculosis-associated IRIS","volume":"379","author":"Meintjes","year":"2018","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013Small-Cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"JCO"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201608-647OC","article-title":"Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist","volume":"14","author":"Lee","year":"2017","journal-title":"Ann Am Thorac Soc"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1162190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T04:52:10Z","timestamp":1684990330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1162190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2023.1162190"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1162190","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"article-number":"1162190"}}